How Does Sasanlimab Fare in High-Risk, BCG-Naïve NMIBC?

Raj Satkunasivam, MD, MS, FRCSC, of Houston Methodist Hospital, shares how sasanlimab has shown a favorable toxicity profile in phase 1 data, which subsequently has led to a phase 3 trial combining the immune checkpoint inhibitor with bacillus Calmette-Guérin (BCG) concurrently in patients with high-risk, BCG-naïve non-muscle invasive bladder cancer (NMIBC).

The encouraging results of this trial led to the formation of the RAD VACCINE MIBC trial, a phase 2 assessment of neoadjuvant sasanlimab and stereotactic body radiation therapy as an in situ vaccine for cisplatin-ineligible MIBC.

Hear what else Dr. Satkunasivam has to say about the phase 2 trial.